RON receptor (MST1R)
RON is a receptor kinase from the same family as MET; multi-kinase drugs such as crizotinib and cabozantinib hit it as well as their main targets.
Overview
Macrophage-stimulating protein receptor (RON, gene MST1R) is the sister receptor of MET, activated by MSP and overexpressed or aberrantly spliced in several carcinomas, where it promotes invasion and macrophage-driven inflammation. It is not a primary approval target, but crizotinib, cabozantinib and other MET-family inhibitors inhibit it and ChEMBL lists it among their targets.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · RON is a receptor kinase from the same family as MET; multi-kinase drugs such as crizotinib and cabozantinib hit it as well as their main targets.
- 1 · What it is
RON is a receptor kinase from the same family as MET; multi-kinase drugs such as crizotinib and cabozantinib hit it as well as their main targets.
- 2 · What goes wrong in cancer
A receptor tyrosine kinase signalling through PI3K, MAPK and beta-catenin pathways; short isoforms act as constitutively active oncogenes.
- 3 · How drugs use it
No product in this corpus aims at RON receptor (MST1R) yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
External identifiers
Biology
A receptor tyrosine kinase signalling through PI3K, MAPK and beta-catenin pathways; short isoforms act as constitutively active oncogenes.
- Overexpressed in subsets of breast, colon, pancreatic and lung carcinomas
- Macrophages
Latest papers
topQuery for this target: (TITLE:"RON receptor" OR ABSTRACT:"RON receptor" OR TITLE:"MST1R" OR ABSTRACT:"MST1R") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RON receptor (MST1R), not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentCapmatinib
Shares Crizotinib, MET, Non-small-cell lung cancer.
- TreatmentHDM2017
Shares MET, Colorectal cancer.
- TreatmentJS111
Shares MET, Non-small-cell lung cancer.
- TreatmentTQB2922
Shares MET, Colorectal cancer.
- TrialLUMINOSITY
Shares MET, Non-small-cell lung cancer.
- TrialTeliMET NSCLC-01
Shares MET, Non-small-cell lung cancer.
- TreatmentTQB6411
Shares MET, Non-small-cell lung cancer.
- TreatmentMCLA-129
Shares MET, Colorectal cancer, Non-small-cell lung cancer.